梅花生物(600873) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥6,038,067,422.69, representing a decrease of 12.97% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2024 was ¥521,497,858.37, down 33.96% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥466,245,366.69, a decrease of 32.62% compared to the same period last year[5]. - The basic earnings per share for Q3 2024 was ¥0.18, reflecting a decline of 33.33% year-on-year[5]. - For the first three quarters, the company's operating revenue was 18.681 billion RMB, a decrease of 8.99% year-on-year, attributed to a decline in market sales prices of key products[7]. - The net profit attributable to shareholders for the first three quarters was 1.995 billion RMB, down 7.65% year-on-year, mainly due to a reduction in gross profit[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for the first three quarters was 1.769 billion RMB, a decrease of 15.70% compared to the same period last year[7]. - The total comprehensive income for Q3 2024 is CNY 2,035,236,221.59, down from CNY 2,447,973,619.90 in Q3 2023[19]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥23,534,870,472.41, an increase of 1.63% from the end of the previous year[5]. - The equity attributable to shareholders at the end of Q3 2024 was ¥14,718,041,524.01, up 3.92% compared to the end of the previous year[5]. - The company's total liabilities decreased to CNY 8,816,828,948.40 from CNY 8,994,165,041.58, a reduction of 2.0%[17]. - The total current liabilities increased to CNY 5.89 billion, up from CNY 4.73 billion, indicating a rise of approximately 24.5%[15]. - The company's non-current assets totaled approximately CNY 14.89 billion, an increase from CNY 13.65 billion, reflecting a growth of about 9.1%[15]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥4,085,711,923.75, down 16.35% year-on-year[5]. - The cash flow from operating activities for the first three quarters of 2024 is CNY 4,085,711,923.75, down 16.31% from CNY 4,884,286,182.54 in the same period of 2023[22]. - The company's cash and cash equivalents decreased to CNY 3.64 billion from CNY 4.97 billion, representing a decline of approximately 26.8%[14]. - Cash and cash equivalents at the end of Q3 2024 amount to CNY 3,364,741,878.94, down from CNY 5,203,814,144.66 at the end of Q3 2023[23]. Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.175 per share, amounting to an estimated total of CNY 500 million, enhancing shareholder returns[12]. - The company has initiated a share repurchase program, with the first announcement made on October 12, 2024, to enhance shareholder value[12]. Research and Development - Research and development expenses for the first three quarters of 2024 were CNY 285,461,019.60, an increase of 21.9% compared to CNY 234,168,723.06 in the same period of 2023[18]. Other Developments - The company upgraded its Visual Identity System and introduced a new logo on October 15, 2024, to align with its international development strategy[13]. - The company has not disclosed any future outlook or guidance in the current report[4].